Prof. Gilles Salles | ICML 2017 | L-MIND study, MOR208 + lenalidomide in R/R DLBCL

L-MIND study, MOR208 + lenalidomide in R/R DLBCL

Gilles Salles | ASH 2018 | MOR208 combined with lenalidomide in patients with R/R DLBCL

Gilles Salles discusses MOR208 combined with lenalidomide in patients with R/R DLBCL at ASH 2018

Gilles Salles | ASH 2018 | MOR208 combined with lenalidomide in patients with R/R DLBCL

Gilles Salles discusses MOR208 combined with lenalidomide in patients with R/R DLBCL at ASH 2018

Tafasitamab plus lenalidomide granted priority review by US FDA

A BLA submitted for tafasitamab (MOR208), in combination with lenalidomide, will be given Priority Review FDA for R/R DLBCL.

Tafasitamab plus lenalidomide granted priority review by US FDA

A BLA submitted for tafasitamab (MOR208), in combination with lenalidomide, will be given Priority Review FDA for R/R DLBCL.

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month

First Name

Last Name

I agree to the Lymphoma Hub Terms & Conditions